Abstract: The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in Bombyx mori, a vector comprising the nucleic acid, Bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.

Abstract: The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in Bombyx mori, a vector comprising the nucleic acid, Bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.

Abstract: An anti-influenza virus agent, an anti-RS virus agent, or an anti-immunodeficiency virus agent, which comprises components originated from plants and which has excellent infectivity-inhibitory effect and proliferation-inhibitory effect against influenza viruses, RS viruses and immunodeficiency viruses. The anti-influenza virus agent, anti-RS virus agent or anti-immunodeficiency virus agent of the present invention comprises an extract derived from, or dry powder of the leaves of a plant belonging to the family Betulaceae and/or a plant belonging to the family Meliaceae.

Abstract: The present invention herein provides an anti-influenza virus agent, an anti-RS virus agent or an anti-immunodeficiency virus agent, which comprises components originated from plants and which has excellent infectivity-inhibitory effect and proliferation-inhibitory effect against influenza viruses, RS viruses and immunodeficiency viruses. The anti-influenza virus agent, anti-RS virus agent or anti-immunodeficiency virus agent of the present invention comprises an extract derived from, or dry powder of the leaves of a plant belonging to the family Betulaceae and/or a plant belonging to the family Meliaceae.

Abstract: A stable immunogen composition for oral administration which includes a dried spherical form comprised of an immunogen capable of immunizing human or animals and a gelatin having an average molecular weight of 80,000-120,000 and jelly strength of more than 150 (Bloom, g, 6.2/3%), and is enteric.

Abstract: This invention relates to a novel influenza vaccine comprising a complex of HANA antigen and an MDP derivative.The novel vaccine is prepared by mixing an influenza HANA antigen and at least one MDP derivative in a suitable medium; solubilizing the resulting mixture with a surface active agent capable of being removed by dialysis, the solubilization being conducted in the presence or absence of cholesterol, lecithin and dicetyl phosphate or a mixture thereof; and then removing the surface active agent therefrom by dialysis to obtain an influenza vaccine comprising artificial vesicle-like particles of a complex of HANA antigen and MDP derivative, where the MDP derivative forms a membrane of the particle (corresponding to the lipid membrane of natural influenza virus particle) on the surface of which there exists the HANA antigen being bonded to the MDP derivative so as to form the complex.